Lotus Pharmaceutical Co Ltd
TWSE:1795

Watchlist Manager
Lotus Pharmaceutical Co Ltd Logo
Lotus Pharmaceutical Co Ltd
TWSE:1795
Watchlist
Price: 281.5 TWD -1.4% Market Closed
Market Cap: 74.7B TWD
Have any thoughts about
Lotus Pharmaceutical Co Ltd?
Write Note

Lotus Pharmaceutical Co Ltd
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Lotus Pharmaceutical Co Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Lotus Pharmaceutical Co Ltd
TWSE:1795
Pre-Tax Income
NT$5B
CAGR 3-Years
40%
CAGR 5-Years
51%
CAGR 10-Years
N/A
Y
YungShin Global Holding Corp
TWSE:3705
Pre-Tax Income
NT$1.5B
CAGR 3-Years
16%
CAGR 5-Years
9%
CAGR 10-Years
5%
Formosa Laboratories Inc
TWSE:4746
Pre-Tax Income
NT$288.5m
CAGR 3-Years
-45%
CAGR 5-Years
N/A
CAGR 10-Years
2%
ScinoPharm Taiwan Ltd
TWSE:1789
Pre-Tax Income
NT$495.3m
CAGR 3-Years
14%
CAGR 5-Years
4%
CAGR 10-Years
-6%
S
SCI Pharmtech Inc
TWSE:4119
Pre-Tax Income
NT$152.4m
CAGR 3-Years
N/A
CAGR 5-Years
-26%
CAGR 10-Years
-5%
Standard Chem & Pharm Co Ltd
TWSE:1720
Pre-Tax Income
NT$1.5B
CAGR 3-Years
19%
CAGR 5-Years
20%
CAGR 10-Years
16%
No Stocks Found

Lotus Pharmaceutical Co Ltd
Glance View

Market Cap
74.4B TWD
Industry
Pharmaceuticals

Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and sales of generic pharmaceutical products; and the provision of consulting services. The company is headquartered in Taipei City, Taipei. The company went IPO on 2004-12-13. The products are mainly solid preparations such as tablets and capsules. The main products include oral anti-cancer drugs, cardiovascular disease drugs, central nervous system drugs, women's health products, osteoporosis drugs and mental disease drugs. The firm is also engaged in the drug research, development and clinical testing business, as well as the product licensing business. The firm mainly distributes products in Taiwan, South Korea, the United States, China mainland, Japan, Europe and Southeast Asia markets.

Intrinsic Value
362.33 TWD
Undervaluation 22%
Intrinsic Value
Price

See Also

What is Lotus Pharmaceutical Co Ltd's Pre-Tax Income?
Pre-Tax Income
5B TWD

Based on the financial report for Jun 30, 2024, Lotus Pharmaceutical Co Ltd's Pre-Tax Income amounts to 5B TWD.

What is Lotus Pharmaceutical Co Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
51%

Over the last year, the Pre-Tax Income growth was -15%. The average annual Pre-Tax Income growth rates for Lotus Pharmaceutical Co Ltd have been 40% over the past three years , 51% over the past five years .

Back to Top